Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

Can regional anticoagulation with calcium‐free dialysate be extended to maintenance hemodialysis?

Toward Acid and Heparin-Free Dialysis: The Regional Anticoagulation Approach

Calcium-Free Dialysate Hemodialysis: A Simplified Approach

Clinical study of regional citrate anticoagulation in hemodialysis with routine dialysate containing calcium

Regional Citrate Anticoagulation: A Tale of More Than Two Stories

Application of Simplified Regional Citrate Anticoagulation in Hemodialysis Patients with High Risk of Bleeding.

Hemodialysis with Regional Citrate Anticoagulation, Low-Molecular-weight Heparin, and Heparin-Free Hemodialysis: Efficacy and Safety in Patients at High Risk of Bleeding

Optimized Calcium Supplementation Approach in Post-Dilution CVVHDF Using Regional Citrate Anticoagulation

[Attention should be paid to the application of regional citrate anticoagulation in blood purification]

A Mathematical Estimation for Quantified Calcium Supplementation During Intermittent Hemodialysis Using Regional Citrate Anticoagulation

Deciphering simplified regional anticoagulation with citrate in intermittent hemodialysis: a clinical and computational study

Regional citrate anticoagulation and influence of recirculation on ionized calcium levels in the circuit

A randomized crossover trial of regional anticoagulation modalities for intermittent hemodialysis

Optimized Calcium Supplementation Approach for Regional Citrate Anticoagulation.

Research progress of regional citrate anticoagulation in renal replacement therapy of critically ill patients

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Safety and Feasibility of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy With Calcium‐Containing Solutions: A Randomized Controlled Trial

P1074SIMPLIED REGIONAL CITRATE ANTICOULATION USING A CALCIUM-CONTAINING REPLACEMENT SOLUTION FOR RENAL REPLACEMENT THERAPY: A RANDOMIZED CONTROLLED CLINICAL TRIAL

Avoiding Systemic Heparinization During Hemodialysis: How the Dialysis Setup Might Help

Application of regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) in patients with high risk of bleeding

Calcium-containing Versus Calcium-Free Replacement Solution in Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: a Randomized Controlled Trial